Coronavirus: The Latest

How promising is Remdesivir?

Over a year since the first recorded case of Covid-19 in humans, only one antiviral drug is approved for its treatment. The Telegraph’s Global Health Security team speak to Dr Michael Elliot, Vice President of Medical Affairs at Gilead Sciences, the company that manufactures Remdesivir. They discuss how useful it is, whether big pharma is solely driven by profit and the prognosis for severe coronavirus sufferers in the second wave.Read more on the Oxford vaccine: <a href="https://bit.ly/2UVfPet" rel="noopener noreferrer" target="_blank">https://bit.ly/2UVfPet</a> |Read more on Brexit talks: <a href="https://bit.ly/36V8f8Y" rel="noopener noreferrer" target="_blank">https://bit.ly/36V8f8Y</a> |Read more on the new quarantine-free list: <a href="https://bit.ly/3lMs88H" rel="noopener noreferrer" target="_blank">https://bit.ly/3lMs88H</a> |For 30 days' free access to The Telegraph: <a href="https://www.telegraph.co.uk/audio" rel="noopener noreferrer" target="_blank">https://www.telegraph.co.uk/audio</a> |Email: <a href="mailto:coronaviruspodcast@telegraph.co.uk" rel="noopener noreferrer" target="_blank">coronaviruspodcast@telegraph.co.uk</a> |See Privacy Policy at <a href="https://art19.com/privacy" rel="noopener noreferrer" target="_blank">https://art19.com/privacy</a> and California Privacy Notice at <a href="https://art19.com/privacy#do-not-sell-my-info" rel="noopener noreferrer" target="_blank">https://art19.com/privacy#do-not-sell-my-info</a>. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer" style="color:grey;" target="_blank">acast.com/privacy</a> for more information.

The latest Coronavirus news from The Telegraph’s leading journalists, with analysis of the impact on health, business and travel in the UK and beyond. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer" style="color:grey;" target="_blank">acast.com/privacy</a> for more information.